Sann-Joong-Kuey-Jian-Tang can inhibit human breast cancer cells through dural-blocking both the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathways

被引：0
|
作者：
Su, Chin Cheng
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2185
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Aloe-Emodin Enhances Tamoxifen Cytotoxicity by Suppressing Ras/ERK and PI3K/mTOR in Breast Cancer Cells
    Tseng, Hsin-Shun
    Wang, Yu-Fen
    Tzeng, Yew-Min
    Chen, Dar-Ren
    Liao, Ya-Fan
    Chiu, Hui-Yu
    Hsieh, Wen-Tsong
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2017, 45 (02): : 337 - 350
  • [42] Targeting the PI3K-AKT-mTOR and RAF-MEK-ERK pathways in HER2 amplified breast cancer models
    De, Pradip
    Sun, Yuliang
    Carlson, Jennifer
    Friedman, Lori
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2015, 75
  • [43] Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
    Yuen, Hiu-Fung
    Chan, Ka-Kui
    Grills, Claire
    Murray, James T.
    Platt-Higgins, Angela
    Eldin, Osama Sharaf
    O'Byrne, Ken
    Janne, Pasi
    Fennell, Dean A.
    Johnston, Patrick G.
    Rudland, Philip S.
    El-Tanani, Mohamed
    CLINICAL CANCER RESEARCH, 2012, 18 (02) : 380 - 391
  • [44] Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways
    Tsubaki, Masanobu
    Takeda, Tomoya
    Sakamoto, Kotaro
    Shimaoka, Hirotaka
    Fujita, Arisa
    Itoh, Tatsuki
    Imano, Motohiro
    Mashimo, Kenji
    Fujiwara, Daiichiro
    Sakaguchi, Katsuhiko
    Satou, Takao
    Nishida, Shozo
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (01): : 168 - 179
  • [45] Potent Suppression of the Growth of Human Pancreatic Cancer Cells by Combinations of Inhibitors of the PI3K/mTOR and MEK/ERK Pathways
    Xu, Qinhong
    Soares, Heloisa
    Young, Steven H.
    Sinnett-Smith, James
    Rozengurt, Enrique
    GASTROENTEROLOGY, 2016, 150 (04) : S330 - S330
  • [46] Antitumor effect by inhibition of PI3K/AKT/mTOR and RAS/MAPK pathways in human oral squamous cell carcinoma cells
    Tokuzen, Norihiko
    Nakashiro, Koh-ichi
    CANCER RESEARCH, 2018, 78 (13)
  • [47] BRAP2 inhibits the Ras/Raf/MEK and PI3K/Akt pathways in leukemia cells, thereby inducing apoptosis and inhibiting cell growth
    Sakai, Hiroharu
    Shiina, Isamu
    Shinomiya, Takahisa
    Nagahara, Yukitoshi
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
  • [48] RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma
    Akula, Shaw M.
    Abrams, Stephen L.
    Steelman, Linda S.
    Emma, Maria R.
    Augello, Giuseppa
    Cusimano, Antonella
    Azzolina, Antonina
    Montalto, Giuseppe
    Cervello, Melchiorre
    McCubrey, James A.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, : 915 - 929
  • [49] IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
    Wenpeng Cai
    Yongfang Ma
    Li Song
    Niandie Cao
    Jiafeng Gao
    Shuping Zhou
    Xiaolong Tang
    BMC Cancer, 23
  • [50] IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
    Cai, Wenpeng
    Ma, Yongfang
    Song, Li
    Cao, Niandie
    Gao, Jiafeng
    Zhou, Shuping
    Tang, Xiaolong
    BMC CANCER, 2023, 23 (01)
12345